Tylenol, Autism, and Political Influence on Healthcare

Last year, former President Donald Trump asserted that acetaminophen, the active ingredient in Tylenol, could increase the risk of autism in children. This claim, made alongside the promotion of leucovorin as an autism treatment, sparked concern among medical professionals and led to measurable shifts in medication utilize, according to recent research. Despite a lack of scientific consensus supporting a link between Tylenol and autism, the administration’s messaging had a significant impact on patient care.

Impact on Medication Use

A study published in The Lancet found that emergency department orders for acetaminophen among pregnant women decreased by 10% in the twelve weeks following the September 2025 White House press conference. This decrease, equivalent to 22 fewer orders per 1000 visits, was not observed among non-pregnant women. Simultaneously, prescriptions for leucovorin rose by 71% during the same period, though the absolute increase represented only 17 prescriptions per 100,000 visits due to the drug’s limited prior use.

“This is an embodiment of how much power our federal health officials have,” said Michael Barnett, a study author and professor at the Brown University School of Public Health. “Even when nothing in the evidence base has changed, it can still shift things to a measurable degree within days.”

Concerns About Substitute Medications

Researchers acknowledge that the study doesn’t reveal whether the decrease in acetaminophen use was driven by clinicians or patients, or whether patients substituted Tylenol with other pain relievers. Lisa Croen, director of the Kaiser Permanente Autism Research Program, expressed concern that patients may have turned to medications known to be hazardous during pregnancy, such as ibuprofen.

“Tylenol is the medication that is safe to control pain and fever during pregnancy. We don’t know if people were substituting paracetamol for other pain meds that are known to be hazardous [during pregnancy],” Croen stated.

Leucovorin and Autism Treatment

The administration likewise promoted leucovorin, a drug with limited evidence of effectiveness for a subset of individuals with autism. The increased prescriptions followed a pattern similar to a direct-to-consumer pharmaceutical advertisement. However, health officials have been focused on curbing autism diagnoses, with Health and Human Services Secretary Robert F. Kennedy Jr. Calling autism an “epidemic.”

Croen cautioned against promoting unproven treatments and expressed concern over the administration’s actions, including taking down federal webpages focused on the harms of controversial autism treatments and proposing a national autism registry that raised fears within the autism community.

“For the government to make statements that are not backed by any rigorous scientific evidence is very harmful to the U.S. Population, children and adults,” Croen said. “Scientists and physicians are having to re-educate people about what we really do know and what is evidence-based unnecessarily, because the government has erased a lot of good work by making these false statements.”

Administration Response

The Trump administration defended its approach, stating through spokesperson Andrew Nixon that it is “the most pro-patient administration in American history” and that delivering a message about a potential neurological risk is a commitment to transparency regarding public health.

Key Takeaways

• Former President Trump’s claims about a link between Tylenol and autism were not supported by scientific evidence.
• The administration’s messaging led to a decrease in acetaminophen use among pregnant women in emergency departments and an increase in leucovorin prescriptions.
• Experts are concerned about potential substitution of Tylenol with less safe pain relievers and the promotion of unproven autism treatments.
• The situation highlights the potential for political messaging to influence healthcare decisions, even in the absence of scientific consensus.